Jardiance is reimbursed for HFpEF

Increases influence in all heart failures regardless of ejection fraction

Has been granted reimbursement across the full spectrum of heart failure

Has first demonstrated efficacy clinical in HFpEF, improves access to patients with unmet needs

Is expected to relieve the individual disease burden and socioeconomic cost burden

Pic of Jardiance

The SGLT2 inhibitor Jardiance (empagliflozin) has been granted reimbursement across the full spectrum of heart failure in Korea, increasing its influence in the market.

 

Boehringer Ingelheim Korea announced on the 31st that its drug will be granted reimbursement as of February 1st, under the Ministry of Health and Welfare notifications, for patients with Heart Failure with Preserved Ejection Fraction.

 

According to the notice, patients with heart failure with symptoms and signs of heart failure and an ejection fraction over 40% who have objective evidence of cardiac structural or functional abnormalities consistent with ▲abnormalities in left ventricular relaxation/increased left ventricular filling pressure (NT-proBNP ≥ 125 pg/mL or BNP ≥ 35 pg/mL) or;▲have visited the emergency room or been hospitalized for worsening heart failure within 12 months are eligible for Jardiance with reimbursment.

 

Jardiance has been granted reimbursement since February last year for patients with heart failure with reduced ejection fraction (HFrEF, EF of 40% or lower).

 

Under the notice, which allows patients with HFpEF reimbursement, patients with chronic heart failure in Korea can now be prescribed Jardiance with reimbursement regardless of ejection fraction.

 

HFpEF is known to be associated with a high burden of disease and hospitalization due to worsening heart failure, similar to HFrEF.

 

Jardiance was the first Type 2 diabetes drug to confirm cardiovascular benefits and expanded indications to cover chronic heart failure.

 

Following the Phase III EMPEROR-Reduced clinical trial in patients with HFrEF, the EMPEROR-Preserved study confirmed the efficacy of the drug in HFpEF.

 

Study results showed that Jardiance significantly reduced the risk of hospitalization due to heart failure or death from cardiovascular disease by 21% compared to placebo in patients with HFpEF, and reduced the risk of first hospitalization and repeated hospitalization due to heart failure by 27%.

 

Currently, SGLT-2 inhibitors are recommended across the full spectrum of heart failure in international heart failure treatment guidelines (Class I).

 

“We are pleased that this expansion of the reimbursement criteria will provide more patients with the opportunity to receive treatment for HFpEF, which has had limited treatment options,” said Jiyoung Park, Head of the Cardio-Renal-Metabolic BU at Boehringer Ingelheim Korea.

 

”Boehringer Ingelheim Korea will continue efforts to support the better lives of patients with chronic heart failure, with a focus on Jardiance.” Meanwhile, the original SGLT2 inhibitor Jardiance is approved for the treatment of Type 2 diabetes, chronic heart failure, and chronic kidney disease.